A new way of measuring the 'intellectual stagnation' of people with schizophrenia

Researchers from the Tatst Medical Center in Boston State, USA, have discovered a new way to monitor brain activity for schizophrenia, which paves the way for a new biological examination to measure the patient’s ability to deal with conflicting information. The study, published in ‘Cell Reports Medicine’, showed that people with schizophrenia show a unique nerve pattern when making decisions based on conflicting information, which provides an objective way to measure what is known as the ‘intellectual stalemate’ associated with the disease. Scientists have known for decades that the classic symptoms of schizophrenia, such as the problems of making decisions, or the inability to adapt to new information, are due to the poor communication between the stroke and the gaze acting as a central axis in the brain. Schizophrenia and decision -making and based on data from animal studies, researchers have concluded that schizophrenia can disrupt the ability to disrupt complicated information related to a priority conflict. About 40 people participated in the study, including individuals with mental health and schizophrenia, and the participants were asked to find a specific purpose based on a series of signals, some of which were contradictory. The results showed that healthy individuals succeeded in performing well, even with a high contrast in information, while the performance of people with schizophrenia fell, and that they made many mistakes when they experienced moderate conflict levels. Schizophrenia and the performing of tasks The results of the study showed that people with schizophrenia show an excessive sensitivity to ‘sensory noise’, which means that their ability to perform tasks has weakened with a greater contradiction in information. When measuring their brain activity, scientists noticed an imbalance in the frontal cortex and a look, which weakened the brain’s ability to process conflicting information. The team is now working to expand their studies to include a larger group of participants, and they plan to apply hierarchical tasks that focus on assessing cognitive flexibility, such as the ability to adapt to different experiences that require an interpretation of multi -level. This extension aims to improve the accuracy of diagnosis, and to develop new instruments to measure the response of patients on treatment. Schizophrenia, according to the World Health Organization, schizophrenia affects about 24 million people, or 1 in 300 people (0.32%) worldwide. Although the disease is not like many other mental disorders, it is related to a group of serious symptoms, serious weakness in personal, family, social, educational, professional and others. Schizophrenia often appears at the end of adolescence and twenties, and the incidence of the disease tends to occur early in men compared to women, and the causes of schizophrenia are not known, nor are there a healing treatment for schizophrenia, although there is medication that can manage the condition. Since the first antipsychotic agent is provided in the fifties of the twentieth century, subsequent medication to treat psychosis work on the same chemical that helps the brain communicate with the rest of the body: dopamine. In September, the US Food and Drug Administration (FDA) agreed to a new remedy to treat schizophrenia in adults, which comes in the form of oral capsules, named: Cobenfy. The trait is described as the first anti -psychococcio to treat schizophrenia, which targets choline receptors instead of dopamine receptors, which according to the US Food and Drug Administration website is the criterion used for a long time.